Safety and efficacy of growth hormone therapy in childhood.
Pediatr Endocrinol Rev
; 2 Suppl 1: 68-77, 2004 Nov.
Article
en En
| MEDLINE
| ID: mdl-16456485
ABSTRACT
Growth hormone (GH) has been used for more than 40 years. GH improves height velocity in many conditions associated with impaired growth and corrects metabolic deficits attributable to GH deficiency (GHD). Many studies and surveillance programs exist to collect efficacy and safety data. GH has been demonstrated to have a relatively wide safety margin. Reported side effects, including pseudotumor cerebri, edema, slipped capital femoral epiphysis (SCFE), worsening of scoliosis, gynecomastia, and hyperglycemia require careful monitoring. Currently, there are no data suggesting that GH therapy increases the risk of developing de novo, recurrent, or secondary malignancies. Patients who have a high intrinsic risk factor for the development of an adverse event need more vigilant surveillance.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Hormona de Crecimiento Humana
/
Trastornos del Crecimiento
Tipo de estudio:
Risk_factors_studies
Límite:
Child
/
Humans
Idioma:
En
Revista:
Pediatr Endocrinol Rev
Asunto de la revista:
ENDOCRINOLOGIA
/
PEDIATRIA
Año:
2004
Tipo del documento:
Article
País de afiliación:
Estados Unidos